National Pharmaceutical Pricing Authority (NPPA) has fixed/revised ceiling prices or retail prices of 65 scheduled formulations under Drugs Prices Control Order, 2013 (DPCO). It includes 63 formulations, 1 scheduled formulation of Schedule-I and 1 scheduled formulations of Schedule-I under para 19 of DPCO.
This time NPPA included formulations from diabetes, pain, hypertension, immunosuppressive and anti-cancer portfolios. It majorly includes formulations containing Teneligliptin, Metformin, Rosuvastatin, Clotrimazole, Paracetamol, Olmesartan, Amlodipine, Atorvastatin etc.
65 scheduled formulations which came under DPCO are from various pharma majors like Akums Drugs and Pharma, Macleods, Sun Pharma, Anglo French Drugs & Industries, Lupin, Cadila Healthcare, Synokem Pharmaceuticals, Emcure, Micro Labs, Reliance Life Sciences etc.
NPPA advised manufacturers that they may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price. The revised retail price is applicable only to the individual manufacturer / marketeer as mentioned by NPPA who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer / marketing companies.
In case the retail price of any of the 65 scheduled formulations is not revised, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
